Mangoceuticals Inc.
MGRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MGRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MGRX
Mangoceuticals Inc. (MGRX) is a pharmaceutical company focused on developing and commercializing products for men's health and wellness, with a current emphasis on its Diabetinol® and Dermytol product lines, operating with limited revenue and recurring net losses.
Key risk: Going concern risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Mangoceuticals Inc..
Mangoceuticals Inc. (MGRX) is a pharmaceutical company focused on developing and commercializing products for men's health and wellness, with a current emphasis on its Diabetinol® and Dermytol product lines, operating with limited revenue and recurring net losses.
- Cash & equivalents of $0.2M as of 2026-06-30 [sec].
- Total revenue of $0.1M for the period ending 2026-06-30 [sec].
- Net income of -$1.3M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $15.2M as of 2026-06-30 [sec].
- Recurring net losses since inception, with an accumulated deficit noted in filings [sec_mda · as of 2026-08-13].
What works
- The company has secured patent and license agreements, including for Diabetinol® and Dermytol, providing a foundation for its product pipeline [sec_mda · as of 2025-05-15].
- Cash increased historically due to financing activities, including stock sales and notes payable, indicating some access to capital markets [sec_mda · as of 2025-11-14].
- The company has no material commitments for capital expenditures, which may provide flexibility in managing cash burn [sec_mda · as of 2026-04-01].
What to weigh
- The company has experienced recurring net losses since inception and expects to continue incurring substantial operating expenses [sec_mda · as of 2026-08-13].
- Cash position is low at $0.2M as of 2026-06-30, raising concerns about near-term liquidity [sec].
- The independent auditor included an explanatory paragraph about the company's ability to continue as a going concern [sec_mda · as of 2026-08-13].
- The company has a limited operating history and has generated only limited revenues to date [sec · filed 2026-01-13].
From the filings
Quoted directly from source documents.
The company has recurring net losses and expects continued losses.
“experienced recurring net losses since inception. We believe that we will continue to incur substantial operating expenses in the foreseeable future”
SEC MD&A · August 13, 2026
The company's auditor raised a going concern issue.
“Our independent registered public accounting firm included an explanatory paragraph in its report on our consolidated financial statements as of December 31, 2025.”
SEC MD&A · August 13, 2026
The company has limited revenue and operating history.
“We have a limited operating history, have produced only a limited amount of products and have generated only limited revenues to date”
SEC filings · January 13, 2026
The company has patent and license agreements for key products.
“6,576,998 as of March 31, 2025, representing license agreements, net of amortization in connection with Diabetinol® and Dermytol.”
SEC MD&A · May 15, 2025
Risks & what to watch (4)›
Key risks
- Going concern risk — Auditor's explanatory paragraph and low cash raise doubt about ability to continue operations [sec_mda · as of 2026-08-13].
- Limited revenue generation — Only $0.1M in revenue as of 2026-06-30, insufficient to cover operating losses [sec].
- Dependence on financing — Need for additional funding may cause shareholder dilution or business curtailment if unavailable [sec_mda · as of 2026-04-01].
- Execution risk on growth strategy — Aggressive growth plans may be more expensive than anticipated and may not succeed [sec_mda · as of 2026-08-13].
What to watch
- Ability to raise additional capital or generate revenue to extend cash runway beyond current $0.2M [sec].
- Progress of Diabetinol® and Dermytol product sales and market adoption [sec_mda · as of 2025-05-15].
- Any updates on the company's ability to achieve profitability or reduce operating losses [sec_mda · as of 2026-08-13].
- Potential exercise of outstanding warrants and resulting dilution [sec_mda · as of 2026-04-01].
Sources: SEC filings · SEC MD&A · Generated August 22, 2026 · How we verify sources →
Run Mangoceuticals Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Mangoceuticals Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
2.7 months
D/E 0.13 · 0% dilution
No tracked pipeline phase
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
15
Total value held
$258K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 246,082 | $89K |
| geode capital management, llc | 194,482 | $70K |
| jane street group, llc | 72,746 | $26K |
| vanguard fiduciary trust co | 57,163 | $21K |
| boothbay fund management, llc | 38,441 | $14K |
| northern trust corp | 37,579 | $14K |
| stonex group inc. | 16,039 | $6K |
| xtx topco ltd | 13,142 | $5K |
| sunbelt securities, inc. | 12,000 | $4K |
| goldman sachs group inc | 11,757 | $4K |
Showing top 10 of 15 institutional holders of Mangoceuticals Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 6.7%
- Days to cover
- 0.1
- Shares short
- 1,016,081
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MGRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Mangoceuticals Inc.?
Mangoceuticals Inc. (MGRX) is a pharmaceutical company focused on developing and commercializing products for men's health and wellness, with a current emphasis on its Diabetinol® and Dermytol product lines, operating with limited revenue and recurring net losses.
Who is the CEO of Mangoceuticals Inc.?
Mr. Jacob D. Cohen is the chief executive officer of Mangoceuticals Inc. (MGRX).
Where is Mangoceuticals Inc. headquartered?
Mangoceuticals Inc. (MGRX) is headquartered in Dallas, TX, United States.
What therapeutic areas does Mangoceuticals Inc. focus on?
Mangoceuticals Inc. develops therapies across Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.